Source comparison
Tesamorelin + Ipamorelin Blend 2025 Latest Research Dosing Buy: Comparison
Tesamorelin (GHRH analogue) Binds GHRH receptors on anterior pituitary somatotrophs; stimulates cAMP-mediated GH gene transcription 1–2mg subcutaneous daily 26–38 minutes (terminal half-life) Visceral adipose tissue volume (MRI-quantified) Gold standard for vi
This comparison does not assign a generated winner or score.
- Tesamorelin (GHRH analogue)
- Binds GHRH receptors on anterior pituitary somatotrophs; stimulates cAMP-mediated GH gene transcription
- 1–2mg subcutaneous daily
- 26–38 minutes (terminal half-life)
- Visceral adipose tissue volume (MRI-quantified)
- Gold standard for visceral fat research; requires daily dosing due to short half-life
- Ipamorelin (ghrelin mimetic)
- Selective GHS-R1a agonist; triggers intracellular calcium mobilisation and rapid GH pulse
- 200–300mcg subcutaneous daily
- Approximately 2 hours
- Peak GH concentration (serum assay 30 min post-dose)
- Cleanest GH secretagogue with no cortisol/prolactin elevation; ideal for lean mass studies
- Tesamorelin + Ipamorelin Blend
- Dual-pathway: sustained GHRH receptor activation + pulsatile ghrelin signalling
- 2mg tesamorelin + 200–300mcg ipamorelin daily
- Governed by tesamorelin (shorter component)
- Composite: VAT reduction + lean mass preservation + IGF-1 AUC
- Synergistic mechanism produces outcomes neither achieves alone; requires precise reconstitution and cold-chain storage
- The comparison clarifies why single-peptide protocols persist despite blend efficacy: tesamorelin alone is sufficient when visceral adipose reduction is the sole endpoint, and regulatory frameworks for human trials favour monotherapy over combination protocols. The blend's advantage emerges in studies requiring simultaneous fat reduction and anabolic signalling. Metabolic syndrome models, age-related sarcopenia research, and body recomposition endpoints where both lipolysis and nitrogen retention matter.